Mokyr, Aghion and Howitt Win 2025 Nobel Economics Prize for Work on Innovation and Growth 

A screen displays the portraits of the 2025 prize winners (L-R) Joel Mokyr, Philippe Aghion and Peter Howitt, during the announcement of the winners of the 2025 Nobel Prize in Economics, the Sveriges Riksbank Prize in Economic Sciences in Memory of Alfred Nobel, at the Royal Swedish Academy of Sciences in Stockholm, Sweden, on October 13, 2025. (AFP)
A screen displays the portraits of the 2025 prize winners (L-R) Joel Mokyr, Philippe Aghion and Peter Howitt, during the announcement of the winners of the 2025 Nobel Prize in Economics, the Sveriges Riksbank Prize in Economic Sciences in Memory of Alfred Nobel, at the Royal Swedish Academy of Sciences in Stockholm, Sweden, on October 13, 2025. (AFP)
TT

Mokyr, Aghion and Howitt Win 2025 Nobel Economics Prize for Work on Innovation and Growth 

A screen displays the portraits of the 2025 prize winners (L-R) Joel Mokyr, Philippe Aghion and Peter Howitt, during the announcement of the winners of the 2025 Nobel Prize in Economics, the Sveriges Riksbank Prize in Economic Sciences in Memory of Alfred Nobel, at the Royal Swedish Academy of Sciences in Stockholm, Sweden, on October 13, 2025. (AFP)
A screen displays the portraits of the 2025 prize winners (L-R) Joel Mokyr, Philippe Aghion and Peter Howitt, during the announcement of the winners of the 2025 Nobel Prize in Economics, the Sveriges Riksbank Prize in Economic Sciences in Memory of Alfred Nobel, at the Royal Swedish Academy of Sciences in Stockholm, Sweden, on October 13, 2025. (AFP)

Joel Mokyr, Philippe Aghion and Peter Howitt won the 2025 Nobel economics prize for "having explained innovation-driven economic growth", the Royal Swedish Academy of Sciences said on Monday.

The prestigious award, formally known as the Sveriges Riksbank Prize in Economic Sciences in Memory of Alfred Nobel, is the final prize to be given out this year and is worth 11 million Swedish crowns ($1.2 million).

"The laureates have taught us that sustained growth cannot be taken for granted," the prize-awarding body said in a statement. Economic stagnation, not growth, has been the norm for most of human history. Their work shows that "we must be aware of, and counteract, threats to continued growth."

Mokyr is a professor at Northwestern University, in Evanston in the United States, while Aghion is professor at the College de France and INSEAD, in Paris, and at the London School of Economics and Political Science, in Britain.

Howitt is a professor at Brown University, in Providence in the United States.

Mokyr was awarded half the prize with the other half being shared between Aghion and Howitt.

"Joel Mokyr used historical observations to identify the factors necessary for sustained growth based on technological innovations," John Hassler, member of the Nobel Committee, said.

"Philippe Aghion and Peter Howitt produced a mathematical model of creative destruction, an endless process in which new and better products replace the old."

The awards for medicine, physics, chemistry, peace and literature were announced last week.

Those prizes were established in the will of Swedish dynamite inventor and businessman Alfred Nobel and have been handed out since 1901, with a few interruptions mostly due to the world wars.

The economics prize was established much later, being given out first in 1969 when it was won by Norway's Ragnar Frisch and Jan Tinbergen from the Netherlands for work in dynamic economic modelling. Tinbergen's brother Nikolaas also won a prize, taking home Medicine in 1973.

While few economists are household names, relatively well-known winners include former US Federal Reserve chairman Ben Bernanke, and Paul Krugman and Milton Friedman.

Last year's economics award went to US-based academics Simon Johnson, James Robinson and Daron Acemoglu for research that explored the relationship between colonization and the establishment of public institutions to explain why some countries have been mired in poverty for decades.



Study Questions Melatonin Use and Heart Health but Don't Lose Sleep Over it

FILE - The label for a bottle of melatonin pills is seen in New York on Thursday, June 2, 2022. (AP Photo/Patrick Sison, File)
FILE - The label for a bottle of melatonin pills is seen in New York on Thursday, June 2, 2022. (AP Photo/Patrick Sison, File)
TT

Study Questions Melatonin Use and Heart Health but Don't Lose Sleep Over it

FILE - The label for a bottle of melatonin pills is seen in New York on Thursday, June 2, 2022. (AP Photo/Patrick Sison, File)
FILE - The label for a bottle of melatonin pills is seen in New York on Thursday, June 2, 2022. (AP Photo/Patrick Sison, File)

Don’t lose sleep over headlines linking melatonin to heart failure.

That’s the message after some scary-sounding reports about a preliminary study involving the sleep-related supplement. It raised questions about the safety of long term use of melatonin for insomnia.

Doctors have long known that too little or interrupted sleep raises the risk of heart disease. But heart experts say this kind of so-called observational study can't prove that melatonin use plays any role — instead of the insomnia patients were trying to treat.

“We should not raise the alarm and tell patients to stop taking all their melatonin,” said Dr. Pratik Sandesara, an interventional cardiologist at Emory Healthcare who wasn’t involved with the research.

Our bodies naturally produce melatonin, a hormone that regulates our sleep cycles. Levels normally increase as it gets darker in the evening, triggering drowsiness.

People may take lab-produced melatonin to help them fall asleep or to adjust for jet lag or time changes.

The new study used international electronic health records, tracking adults diagnosed with insomnia who had a melatonin prescription that suggested they used the supplement for at least a year.

Over five years, 4.6% of the chronic melatonin users developed heart failure compared to 2.7% of insomnia patients whose charts showed no melatonin use, the researchers found. The study is being presented at an American Heart Association meeting but hasn’t undergone peer review.

But only certain countries require a melatonin prescription. It’s over-the-counter in the US, meaning Americans in the study might have used the supplements without it being recorded, said Northwestern University cardiology chief Dr. Clyde Yancy, who wasn't involved in the study. The study also did not show dosages, The Associated Press reported.

Also, US supplements don’t require government approval, meaning brands can vary in their ingredients. The researchers, from SUNY Downstate Health Sciences University, characterized the findings as a call for more research.

Meanwhile, patients wondering about melatonin should talk it over with their doctors, said Emory’s Sandesara. Generally doctors recommend it for short-term use, like for jet lag.

Yancy noted that while the study doesn't prove there's a danger from long term melatonin use, there's also no evidence that people should use melatonin indefinitely.

And one key to better shut-eye is to practice better sleep hygiene, like making sure your room is dark.

“When we expose ourselves to blue light in particular at night, we are diminishing our melatonin levels. That’s science,” he said. Sleep problems aren’t about “just being sleepy and tired — they’re putting yourself at risk.”


Prince Harry Apologizes to Canada Over Hat

Prince Harry (right) and Meghan Markle sit during the eight inning between the Toronto Blue Jays and the Los Angeles Dodgers during Game 4 of the 2025 MLB World Series at Dodger Stadium (Shutterstock)
Prince Harry (right) and Meghan Markle sit during the eight inning between the Toronto Blue Jays and the Los Angeles Dodgers during Game 4 of the 2025 MLB World Series at Dodger Stadium (Shutterstock)
TT

Prince Harry Apologizes to Canada Over Hat

Prince Harry (right) and Meghan Markle sit during the eight inning between the Toronto Blue Jays and the Los Angeles Dodgers during Game 4 of the 2025 MLB World Series at Dodger Stadium (Shutterstock)
Prince Harry (right) and Meghan Markle sit during the eight inning between the Toronto Blue Jays and the Los Angeles Dodgers during Game 4 of the 2025 MLB World Series at Dodger Stadium (Shutterstock)

The Duke of Sussex has apologized to Canada for wearing a Los Angeles Dodgers hat while attending a World Series game against the Toronto Blue Jays.

Prince Harry joked that he was “under duress” when he wore the bright blue cap during the epic Game 4 of the World Series in Los Angeles.

He thought it was “the polite thing to do” after being invited to the game by the Dodgers' owner.

According to BBC, his headgear choice upset many in Canada - a Commonwealth nation- who criticized him for not showing his allegiance to the realm, or to the only Canadian team in Major League Baseball.

Prince Harry's father King Charles is the head of state of Canada and of 13 other Commonwealth realms.

“Firstly, I would like to apologize to Canada for wearing it,” he said in a CTV interview. “Secondly, I was under duress. There wasn't much choice.”

The prince - wearing a Blue Jays hat during the interview - quipped that “when you're missing a lot of hair on top, and you're sitting under flood lights, you'll take any hat that's available.”

He plans to wear a Blue Jays hat from now on and rooted for the Toronto team in subsequent games, appearing to do so in a clip posted on social media by the Duchess of Sussex - a Los Angeles native - when the Dodgers won the series in Game 7 a few days later.

Prince Harry, who was given a Blue Jays hat while meeting with Canada's oldest veterans for a Remembrance event on Thursday, also said that admitting that he is a Toronto fan would likely make his reception in California more difficult.

The prince and his wife, a former actress who lived in Canada while filming her TV drama Suits, moved to California after stepping back as full-time royals in 2020.

The couple's presence in the Chavez Ravine-set stadium in Los Angeles also disgruntled many Dodgers fans in the US.

They took to social media to voice their upset over the couple's plum front-row seats during the 18-inning game, while local legends such as Magic Johnson and former pitcher Dodgers Sandy Koufax were seated behind them.


Gilead's Breast Cancer Drug Fails to Meet Main Goal of Late-stage Study

Gilead Sciences Inc pharmaceutical company is seen in Oceanside, California, US, April 29, 2020. REUTERS/Mike Blake/File Photo
Gilead Sciences Inc pharmaceutical company is seen in Oceanside, California, US, April 29, 2020. REUTERS/Mike Blake/File Photo
TT

Gilead's Breast Cancer Drug Fails to Meet Main Goal of Late-stage Study

Gilead Sciences Inc pharmaceutical company is seen in Oceanside, California, US, April 29, 2020. REUTERS/Mike Blake/File Photo
Gilead Sciences Inc pharmaceutical company is seen in Oceanside, California, US, April 29, 2020. REUTERS/Mike Blake/File Photo

Gilead Sciences said on Friday its breast cancer drug Trodelvy did not significantly lower the risk of disease progression in patients when used as a first-line treatment, failing to meet the main goal of a late-stage study, Reuters reported.

Gilead said an early trend for extending overall survival, a key measure of treatment efficacy, was observed favoring patients treated with Trodelvy, compared to chemotherapy.

The data for overall survival, however, was not mature at the time of the primary analysis, the company said, adding that the study will continue to assess this secondary goal.

Trodelvy was being tested in patients with HR+/HER2-negative metastatic breast cancer, the most common subtype of the cancer, as a first-line treatment following hormone therapy.